BioCentury
ARTICLE | Clinical News

Lirilumab: Phase II amended

April 13, 2015 7:00 AM UTC

Innate said an independent DSMB recommended stopping treatment in an undisclosed arm of the double-blind, French Phase II EffiKIR trial evaluating 0.1 and 1 mg/kg lirilumab after the DSMB’s fourth assessment showed that the arm cannot be superior vs. placebo. The DSMB did not report safety concerns. Last year, Innate completed enrollment of 150 elderly AML patients in first complete remission in EffiKIR. ...